VEGF Receptor 2 (CD309 antigen, Fetal liver kinase 1, FLK1, KDR, Kinase insert domain receptor, KRD1, Ly73, Protein tyrosine kinase receptor FLK1, Vascular endothelial growth factor receptor 2, VEGFR, VEGFR2)

The expression of VEGF and KDR correlates highly with the normal ocular vascularization in humans, but VEGF may also be necessary for nonvascular retinal developmental functions, especially for the coordination of neural retinal development and the preliminary steps of the establishment of the definitive stable retinal vasculature (1). KDR/flk-1 is one of two receptors for vascular endothelial growth factor, a potent angiogenic peptide. KDR/flk-1 is an early marker for endothelial cell progenitors, and its expression is restricted to endothelial cells in vivo (2). Therapeutic angiogenesis is likely to require the administration of factors that complement each other. Activation of the receptor tyrosine kinase KDR/Flk1 by vascular endothelial growth factor (VEGF) is crucial, but molecular interactions of other factors with VEGF and Flk1 have been studied to a limited extent. Activation of KDR/Flt1 by PGF resulted in intermolecular transphosphorylation of Flk1, thereby amplifying VEGF-driven angiogenesis through KDR/Flk1. Even though VEGF and PGF both bind KDR/Flt1, PGF uniquely stimulated the phosphorylation of specific KDR/Flt1 tyrosine residues and the expression of distinct downstream target genes (3).\n\nApplications: \nSuitable for use in Western Blot and Immunoprecipitation. Other applications not tested.\n\nRecommended Dilutions:\nWestern Blot: 1:500\nImmunoprecipitation: 1:20\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage, aliquot and store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. \n\nManufactured incorporating RabMAb(R) technology under Epitomics US patents, No 5,675,063 and 7,429,487, owned by Abcam.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2110-18S

Size

100ul

Applications

IP, WB

Hosts

Rabbit

Reactivities

Hum

Form

Supplied as a liquid in 50mM Tris-Glycine, pH 7.4, 0.15M sodium chloride, 0.05% BSA, 0.01% sodium azide, 40% glycerol.

P Type

Mab

Purity

Supernatant

Isotype

IgG

References

1.Gogat K, et al. Invest Ophthalmol Vis Sci 45(1):7-14, 2004 2.Patterson C, et al. J Biol Chem 270(39):23111-8, 19953.Autiero M, et al. Nat Med 9(7):936-43, 2003.

Additional Info

Recognizes human KDR/VEGFR2.